Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

AstraZeneca’s Outlicensing Tactics Make It Top Dealmaker

Sep 10 2019

• By Andrew McConaghie

AstraZeneca

Related Content

A Whopper Of A Deal: AZ Hands Half Of Lynparza To Merck

Jul 27 2017

Nektar Pins Falling Cancer Response Rate On Manufacturing Problem

Aug 09 2019

Regeneron And Teva's Fasinumab Crosses One Threshold; More Remain

Aug 16 2018

Bristol Goes In Big On New Valentine Nektar

Feb 14 2018

Related Companies

AstraZeneca PLC

Merck & Co., Inc.

Johnson & Johnson

Roche Holding AG

Pfizer Inc.

Bristol Myers Squibb Company

Novartis AG

Allergan plc

Nektar Therapeutics

Ablynx N.V.

Eisai Co., Ltd.

Teva Pharmaceutical Industries Ltd.

Regeneron Pharmaceuticals, Inc.

Additional Topics

Deals Commercial Companies Market Intelligence BioPharmaceutical

More from Deals

More from Business

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window